



DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)
("Company" and together with its subsidiaries, the "Group")

APPOINTMENT OF DIRECTOR AND ESTABLISHMENT OF MEDICAL AND SCIENTIFIC ADVISORY BOARD AT DIGITAL LIFE LINE PTE. LTD., AN ASSOCIATE COMPANY OF DISA DIGITAL SAFETY PTE. LTD.

Further to the announcements pertaining to the appointment of directors and change in shareholdings at Digital Life Line Pte. Ltd. ("DLL") dated 29 December 2021 and 12 January 2022 and the news release pertaining to the securing of the new funding dated 4 July 2022, the board of directors (the "Board") of the Company wishes to announce the following:

(1) Mr. Martin Yuen An Lavoo has been appointed as the director of DLL with effect from 22 July 2022

Mr. Martin Lavoo is currently working as a Portfolio Manager at Wu Advisors Pte. Ltd. and Managing Director of Nipsea International Limited, where he manages both public and private investments for the Wuthelam Group of companies, a leading Asian paint and coating company. He is also the co-founder and Executive Director of Sustenir Group Pte Ltd, which today is one of Asia's leading vertical farms with operations across Singapore, Hong Kong, and Malaysia. Prior to founding Sustenir, Martin was with Riverbed Technology Inc. as a Regional Sales Manager of North Asia and worked as an audit associate at KPMG at the start of his career.

Martin is an MBA graduate from the University of Chicago Booth School of Business and holds an undergraduate degree in Accounting & Management from the University of New South Wales.

Following the abovementioned appointment, with effect from 22 July 2022, the composition of the Board of DLL shall be as follows:

Professor Soo Khee Chee, Chairman
Dr. Chua Lee Kiang, Melvin
Dr. Guy Heathers
Mr. John Wong Weng Foo
Mr. Martin Yuen An Lavoo
Mr. Chng Weng Wah, Managing Director and CEO
Mr. Han Yang Kwang

(2) Establishment of Medical and Scientific Advisory Board for DLL with effect from 22 July 2022

The Board is pleased to announce the establishment of Medical and Scientific Advisory Board for DLL, the advisors of which include **Professor Soo Khee Chee, Dr. Danny Jian Hang Tng, Dr. Ooi Eng Eong, Dr. Chua Lee Kiang, Melvin and Associate Professor Jenny Low Guek Hong** ("DLL Board of Advisors"). They are the inventors of the new saliva-based COVID-19 ART (Antigen Rapid Test) technology.

Professor Soo, who is also a director of DLL, studied medicine in the University of Singapore and graduated in 1975. He did his surgical training in Sydney and then had his fellowship training in surgical oncology and head and neck surgery in London and New York. He returned to Singapore General Hospital in 1988 and has been there since. In 1993, he became the Head of the Department of Surgery and held that position for 11 years. He was for a period the Chairman of the NUS Department of Surgery. In 1997, he became the Founding Director of the National Cancer Centre Singapore and recently retired from that position after 20 years. He was also the Senior Vice Dean of Duke NUS Medical School and now continues to hold the Benjamin Sheares Professorship in Academic Medicine. He has just started his own surgical practice in Farrer Park Hospital.

In his career in Singapore spanning 30 years, he has trained numerous general surgeons, surgeons with interest in cancer surgery and head and neck surgery. In that period of time, he has the pleasure of seeing many of these specialties have become recognised as leading practitioners in their respective fields in Singapore and regionally.

He has been recognised as the pioneer and leading cancer surgeon in the country. He introduced complex surgery like peritonectomies for previously inoperable cancers in the abdominal cavity and major intraabdominal tumours including removal of invaded major blood vessels. In the field of head and neck surgery, he is recognised to have performed the most of complex operations for cancers in this region. He is also recognised for removal of limb soft tissue tumours. He also introduced isolated limb perfusion for the management of intransit metastases for skin tumours attempting to salvage limbs which would otherwise require amputations.

Professor Soo has won several national awards including Public Administration (Gold), National Outstanding Mentor and the President's Science and Technology Award. He is currently the Inaugural Benjamin Sheares Professor in Academic Medicine for Duke-Nus Medical School.

Dr. Danny Tng received his medical training at Duke-NUS Medical School (Singapore) and received his PhD scientific training in micro/nano technologies for individualised disease treatment at Nanyang Technological University (Singapore). He has a strong passion for research and had been nominated as the valedictorian of his graduating PhD cohort for his work. Being both a practicing physician and scientist, his research interests lie in translational technologies medical technologies in the areas of nanomaterial sensing, drug delivery and therapeutics. He has published widely in these areas, in journals such as Coordination Chemistry Reviews, Applied Physics Reviews and American Chemical Society Biomaterials & Engineering.

Dr. Ooi was trained in medicine at the University of Nottingham and completed his PhD studies on molecular epidemiology at the National University of Singapore. His research interest includes dengue pathogenesis and host response to virus infection and vaccination. His laboratory integrates clinical studies with basic virology and immunology to address specific research questions. Findings from these studies have been published in journals such as New England Journal of Medicine, Science and Nature Medicine. He is a three-time recipient of the Clinician-Scientist (Senior Investigator) Award by the National Medical Research Council of Singapore. He was also named as one of the Asians of the Year 2020 and part of the team that was awarded the Singaporean of the Year 2020, both by The Straits Times.

Dr. Melvin Chua, who is also a director of DLL, is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy – Precision Radiation Oncology Programme. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology and the Director of the Data and computational Science Core. His research is supported by the NMRC (National Medical Research Council) Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers.

He graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-doctoral Clinician-scientist fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Center, Toronto. In 2021, he obtained his fellowship of the Academy of Medicine Singapore under the College of Radiation Oncology and Clinician Scientists.

Dr. Chua is a KOL (Key Opinion Leader) on NPC (Nasopharyngeal Carcinoma) and prostate cancer, and he has been invited to speak at more than 100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network, a board member on the Head Neck Cancer International Group (HNCIG) and the Scientific Committee Chairman of HNCIG Artificial Intelligence working group.

Associate Professor Jenny Low is a senior consultant with the Department of Infectious Diseases in Singapore General Hospital. Concurrently, she is the co-director of the Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS (ViREMiCS) in the SingHealth Duke NUS AMC and deputy clinical and scientific director at the SingHealth Investigational Medicine Unit (IMU). Associate Professor Low has been doing clinical research for almost 20 years. She has a long track record in conducting proof of concept and early phase clinical trials. Her current research focus is on early phase adaptive clinical trials of viral therapeutics and vaccine development as well as understanding the role of the early immune responses in modulating the outcome of infection or vaccination. She has been twice awarded the National Clinician Scientist Award in 2016 and 2019 for her research in host immune response to viral infections. She was the lead author in the first publication that detailed host response to severe COVID-19 (Ong et al, A dynamic immune response shapes COVID19 progression, Cell Host Microbe 2020). She is also currently leading the Lunar CoV-19 vaccine trial that is co-developed by Duke-NUS and Arcturus therapeutics as well leading the clinical trial for the therapeutic monoclonal antibody against SARS-CoV2 developed by local biotech company, Tychan Pte Ltd.

BY ORDER OF THE BOARD

Chng Weng Wah
Managing Director and Chief Executive Officer
25 July 2022

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited)
Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.
Telephone number: +65 6232 3210*

About Digital Life Line Pte. Ltd.

DLL, an associate company of DiSa Digital Safety Pte. Ltd., is a healthcare digitalization company that aims to transform the field of point-of-care testing by leveraging its proprietary on-kit signal amplification platform to enhance the detection sensitivity of rapid diagnostic kits, as well as an ecosystem of scalable, serialized diagnostics to facilitate result tracing and reporting. We are focusing on the manufacturing and distribution of reader-free, low-cost signal amplification tools that can be seamlessly adapted to existing and future antigen rapid test (ART) kits for the healthcare industry and at-home testing.

PASPORT™ GOLD SARS-CoV-2 ART kit has been certified as a CE-IVD device under the In-Vitro Diagnostics Directive (IVDD 98/79/EC) on 19 May 2022.

More information is available at <http://www.digital-lifeline.com>.

About DiSa Digital Safety Pte. Ltd.

DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution (“**DiSa Asset Protection System**”). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns.

DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017.

About DISA Limited

DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at <http://www.digital-safety.com>.